411 related articles for article (PubMed ID: 31211344)
1. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
[TBL] [Abstract][Full Text] [Related]
2. Predicting future rates of tau accumulation on PET.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Whitwell J; Josephs K; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
Brain; 2020 Oct; 143(10):3136-3150. PubMed ID: 33094327
[TBL] [Abstract][Full Text] [Related]
3. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.
Petersen RC; Wiste HJ; Weigand SD; Rocca WA; Roberts RO; Mielke MM; Lowe VJ; Knopman DS; Pankratz VS; Machulda MM; Geda YE; Jack CR
JAMA Neurol; 2016 Jan; 73(1):85-92. PubMed ID: 26595683
[TBL] [Abstract][Full Text] [Related]
4. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
[TBL] [Abstract][Full Text] [Related]
5. Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals.
Jack CR; Wiste HJ; Algeciras-Schimnich A; Weigand SD; Figdore DJ; Lowe VJ; Vemuri P; Graff-Radford J; Ramanan VK; Knopman DS; Mielke MM; Machulda MM; Fields J; Schwarz CG; Cogswell PM; Senjem ML; Therneau TM; Petersen RC
Alzheimers Dement; 2024 Mar; 20(3):2143-2154. PubMed ID: 38265198
[TBL] [Abstract][Full Text] [Related]
6. PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases.
Reimand J; de Wilde A; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; Barkhof F; van der Flier WM; Scheltens P; van Berckel BNM; Ossenkoppele R; Bouwman F
Alzheimers Res Ther; 2019 Dec; 11(1):100. PubMed ID: 31810489
[TBL] [Abstract][Full Text] [Related]
7. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex,
Therriault J; Pascoal TA; Benedet AL; Tissot C; Savard M; Chamoun M; Lussier F; Kang MS; Berzgin G; Wang T; Fernandes-Arias J; Massarweh G; Soucy JP; Vitali P; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
Neurology; 2021 Feb; 96(7):e975-e985. PubMed ID: 33443136
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS).
Liu Z; Shi D; Cai Y; Li A; Lan G; Sun P; Liu L; Zhu Y; Yang J; Zhou Y; Guo L; Zhang L; Deng S; Chen S; Yu X; Chen X; Zhao R; Wang Q; Ran P; Xu L; Zhou L; Sun K; Wang X; Peng Q; Han Y; Guo T
Alzheimers Res Ther; 2024 Apr; 16(1):84. PubMed ID: 38627753
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework.
Jack CR; Therneau TM; Weigand SD; Wiste HJ; Knopman DS; Vemuri P; Lowe VJ; Mielke MM; Roberts RO; Machulda MM; Graff-Radford J; Jones DT; Schwarz CG; Gunter JL; Senjem ML; Rocca WA; Petersen RC
JAMA Neurol; 2019 Oct; 76(10):1174-1183. PubMed ID: 31305929
[TBL] [Abstract][Full Text] [Related]
10. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
[TBL] [Abstract][Full Text] [Related]
11. Brain amyloid, cortical thickness, and changes in activities of daily living.
Vassilaki M; Aakre JA; Kremers WK; Lesnick TG; Mielke MM; Geda YE; Machulda MM; Knopman DS; Butler L; Traber M; Vemuri P; Lowe VJ; Jack CR; Roberts RO; Petersen RC
Ann Clin Transl Neurol; 2020 Apr; 7(4):474-485. PubMed ID: 32314554
[TBL] [Abstract][Full Text] [Related]
12. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT;
Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428
[TBL] [Abstract][Full Text] [Related]
13. Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort.
Canu E; Rugarli G; Coraglia F; Basaia S; Cecchetti G; Calloni SF; Vezzulli PQ; Spinelli EG; Santangelo R; Caso F; Falini A; Magnani G; Filippi M; Agosta F
J Neurol; 2024 May; 271(5):2716-2729. PubMed ID: 38381175
[TBL] [Abstract][Full Text] [Related]
14. Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
Chen X; Toueg TN; Harrison TM; Baker SL; Jagust WJ
Ann Neurol; 2024 Feb; 95(2):249-259. PubMed ID: 37789559
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in the association between tau PET and cognitive performance in a non-Hispanic White cohort with preclinical AD.
Wang X; Sundermann EE; Buckley RF; Banks SJ;
Alzheimers Dement; 2024 Jan; 20(1):25-33. PubMed ID: 37641484
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of imaging-based ATN profiles in a memory clinic cohort.
Peretti DE; Ribaldi F; Scheffler M; Chicherio C; Frisoni GB; Garibotto V
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3313-3323. PubMed ID: 37358619
[TBL] [Abstract][Full Text] [Related]
17. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort.
Dage JL; Wennberg AMV; Airey DC; Hagen CE; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Mielke MM
Alzheimers Dement; 2016 Dec; 12(12):1226-1234. PubMed ID: 27436677
[TBL] [Abstract][Full Text] [Related]
18. Tau, β-Amyloid, and Glucose Metabolism Following Service-Related Traumatic Brain Injury in Vietnam War Veterans: The Australian Imaging Biomarkers and Lifestyle Study of Aging-Veterans Study (AIBL-VETS).
Cummins TL; Doré V; Feizpour A; Krishnadas N; Bourgeat P; Elias A; Lamb F; Williams R; Hopwood M; Landau S; Villemagne VL; Weiner M; Rowe CC
J Neurotrauma; 2023 Jun; 40(11-12):1086-1097. PubMed ID: 36855333
[TBL] [Abstract][Full Text] [Related]
19. Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults.
Hanseeuw BJ; Jacobs HIL; Schultz AP; Buckley RF; Farrell ME; Guehl NJ; Becker JA; Properzi M; Sanchez JS; Quiroz YT; Vannini P; Sepulcre J; Yang HS; Chhatwal JP; Gatchel J; Marshall GA; Amariglio R; Papp K; Rentz DM; Normandin M; Price JC; Healy BC; El Fakhri G; Sperling RA; Johnson KA
Neurology; 2023 Dec; 101(24):e2533-e2544. PubMed ID: 37968130
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic and prognostic value of tau-PET in amnestic MCI with different FDG-PET subtypes.
Boccalini C; Caminiti SP; Chiti A; Frisoni GB; Garibotto V; Perani D;
Ann Clin Transl Neurol; 2024 May; 11(5):1236-1249. PubMed ID: 38553802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
